SUD billing for MAT, IOP, PHP, and residential treatment

Substance use disorder billing lives at the intersection of behavioral health parity, ASAM level-of-care criteria, and payer prior auth. Documentation built around ASAM wins authorization. Generic documentation loses it.

Where substance abuse (sud) practices lose revenue

We see the same patterns across substance abuse (sud) groups. The leaks are specific, recurring, and fixable with coding discipline and payer-aware claim construction.

  1. ASAM level of care documentation (1.0 to 4.0)
  2. MAT billing (Suboxone, Vivitrol, methadone)
  3. IOP H0015 and PHP H0035 coding
  4. Parity enforcement against under-authorized stays
  5. Residential and detox level-of-care authorization
CPT specimen sheet

High-volume Substance Abuse (SUD) codes we code and appeal

Not a complete list. A representative slice of the codes that drive revenue and denials for substance abuse (sud) practices.

CodeDescriptionProfile
H0015Alcohol and drug services, intensive outpatientHigh volume
H0035Partial hospitalization, mental healthModifier-sensitive
H0001Alcohol and drug assessmentDenial-prone
99408Alcohol and drug abuse screening, 15 to 30 minHigh volume
J0570Buprenorphine implantModifier-sensitive
J2315Naltrexone injection (Vivitrol)Denial-prone
G2086Office-based opioid use disorder treatment, monthlyHigh volume

How we run substance abuse (sud) billing

ASAM documentation built into each level of care. Prior auth workflow by payer (commercial, Medicaid, Medicare) with typical review cycles. Parity appeals prepared when authorization falls below ASAM-supported level. MAT billing tracked across Suboxone, Vivitrol, and methadone workflows.

What the common denials look like and how we fix them

Pattern we see. Level of care denied (authorization at lower level than ASAM supports), MAT denied for missing induction documentation, and IOP concurrent review denied without engagement documentation.

How we fix it. Every denial is logged against its CARC/RARC code and routed to a coder who owns the appeal. We rebuild the claim with the documentation the payer is actually asking for, not a generic reconsideration letter. Recovery rate on appealable substance abuse (sud) denials averages above 60 percent.

How do you handle concurrent review?
Daily or weekly concurrent review with the UR department. We submit the ASAM criteria matching the current level, treatment plan progress, and engagement documentation. Denials appealed with parity citation when appropriate.
Do you handle MAT billing?
Yes. Suboxone (office-based), Vivitrol (Q3W injection), methadone (OTP), and monthly bundled codes (G2086, G2087, G2088) where applicable.
Do you handle MAT (medication-assisted treatment) billing?
Yes. Buprenorphine (J-codes and E/M), naltrexone injection (J2315), and the counseling add-ons (G2086, G2087, G2088) for monthly bundled MAT episodes.
Can you bill residential and inpatient SUD?
Yes. ASAM level 3.5 and 3.7 residential, 4.0 inpatient, with the per-diem and concurrent review documentation most payers require. Appeals support for medical necessity denials.
Start here

See what substance abuse (sud) billing could actually look like.

A written 30-day diagnostic. Dollar figures against every finding. No obligation.

Call Get a free audit